Highlights
1 patent
About
Novel Human Peptide Hormones to Treat Diabetes
TwoToBiotech's researchers have identified a novel human peptide hormone (P3) thatis expressed in activated immune cells. The company subsequently developed a platform technology with several specific monoclonal antibodies against P3 in order to treat autoimmune diseases. In-vivo studies show that the antibody may be effectivefor treatment of type 1 and type 2 diabetes. TwoToBiotech is developing another novel human peptide hormone, APC1, for treatment of type 2 diabetes. Initial tests on mice have shown promise. The company has also isolated a novel human cardiac peptide that may have the potential tostrongly regulate glucose metabolism.
Identity
| Name | TwoToBiotech |
|---|---|
| Slug | twotobiotech |
| Type / kind | startup |
| Crunchbase ID | twotobiotech |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6q6LoLDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Mar 2022 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Jerusalem District |
| HQ city | Jerusalem |
| HQ address | Rosenblatt 7, Jerusalem, Israel |
Web & social
| https://www.linkedin.com/company/2619390 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business models
B2B
Tags
pharma-companiesmolecular-biologydiabetespharmaceuticalsautoimmune-diseases
Funding
| Total raised | $500K |
|---|---|
| Current stage | Pre-Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}